Phase I/II prospective trial of autologous platelet tissue graft in gynecologic surgery.

Phase I/II prospective trial of autologous platelet tissue graft in gynecologic surgery. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Phase I/II prospective trial of autologous platelet tissue graft in gynecologic surgery. Abstract Text:

James Fanning,Luis Murrain,Robert Flora,Timothy Hutchings,Jil M Johnson,Bradford W Fenton,James Fanning,Luis Murrain,Robert Flora,Timothy Hutchings,Jil M Johnson,Bradford W Fenton,

STUDY OBJECTIVE: To perform the original phase I/II trial of autologous platelet tissue graft in gynecologic surgery to evaluate toxicity and efficacy on decreasing pain. DESIGN: Prospective nonrandomized trial (Canadian Task Force classification II-A). SETTING: Teaching hospital. PATIENTS: Fifty-five consecutive patients undergoing major gynecologic surgery were entered into this prospective phase I/II trial and were matched with 55 patients from the previous 6 months. INTERVENTION: After anesthesia was induced, peripheral venous blood (55 mL) was obtained from the patient producing, autologous platelet tissue graft (20 mL). At completion of surgery, autologous platelet tissue graft was directly applied to the surgical site. MEASUREMENTS AND MAIN RESULTS: Median pain on the day of surgery was 2.7 (mild) in the autologous platelet tissue graft group vs 6.7 (severe) in the control group, p <.001. Likewise, pain on postoperative day 1 was 2.1 (mild) in the autologous platelet tissue graft group vs 5.5 (moderate) in the control group, p < or =.001. Median of morphine per hospital stay for the autologous platelet tissue graft group was 17 mg (range 1-98 mg) vs 26 mg (range 3-90 mg) in the control group, which was statistically significant at p = .02. There were no adverse effects associated with autologous platelet tissue graft. CONCLUSIONS: In the original phase I/II prospective trial of autologous platelet tissue graft in gynecologic surgery, there were no apparent adverse effects, and pain was significantly reduced.

Phase I/II prospective trial of autologous platelet tissue graft in gynecologic surgery. Publishing Authors By Initials

J Fanning,L Murrain,R Flora,T Hutchings,JM Johnson,BW Fenton,J Fanning,L Murrain,R Flora,T Hutchings,JM Johnson,BW Fenton,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Phase I/II prospective trial of autologous platelet tissue graft in gynecologic surgery. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Journal of minimally invasive gynecology

VOLUME: 14

Page Numbers: 633-7

Journal Abbreviation:

ISSN: 1553-4650

DAY: 12

MONTH: 09

YEAR: 2007

Phase I/II prospective trial of autologous platelet tissue graft in gynecologic surgery. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101235322

Phase I/II prospective trial of autologous platelet tissue graft in gynecologic surgery. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Phase I/II prospective trial of autologous platelet tissue graft in gynecologic surgery. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Phase I/II prospective trial of autologous platelet tissue graft in gynecologic surgery.

AFFILIATION: Department of Obstetrics and Gynecology, Summa Health System, Northeastern Ohio Universities College of Medicine, Akron, Ohio 44309, USA. fanning@summa-health.org

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Minim Invasive Gynecol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Phase I/II prospective trial of autologous platelet tissue graft in gynecologic surgery Related Publications

• APPLANATION TONOMETRY USING ANAESTHETIC-FLUORESCEIN MIXTURE.
• Arthur Cooper and his pet gibbon ape.
• CORRESPONDENCE.
• EYE-DROPS IN TONOMETRY.
• Genetic enhancement - a threat to human rights?
• Gestational PFOA exposure of mice is associated with altered mammary gland development in dams and female offspring.
• HIV, Homelessness, and Public Health: Critical Issues and a Call for Increased Action.
• ICF: Representing the Patient beyond a Medical Classification of Diagnoses.
• Identifying unmet therapeutic domains in schizophrenia patients: the early contributions of Wayne Fenton from Chestnut Lodge.
• Inherent dispersion in restitution properties over space.
• KTP laser and nitinol alloy stents: Are they compatible?
• Link-based feature extraction for model-based detection of echolocation calls.
• Maternity and Infant Welfare Service in England and Wales.
• Missed opportunities for earlier HIV diagnosis within primary and secondary healthcare settings in the UK.
• New paradigms for treatment development.
• Nucleosomes possess a high affinity for glomerular laminin and collagen IV and bind nephritogenic antibodies in murine lupus-like nephritis.
• Pathogen interactions, population cycles, and phase shifts.
• Person-centered psychiatric care: a tribute to Wayne S. Fenton, MD.
• Phase I/II prospective trial of autologous platelet tissue graft in gynecologic surgery.
• Progress on NIMH initiatives (memorial theme for Wayne Fenton, MD).
• Public health contributions.
• Pulmonary vein reentry-Properties and size matter: Insights from a computational analysis.
• Sexual behaviour and HIV infection in black-Africans in England: results from the Mayisha II survey of sexual attitudes and lifestyles.
• Sustaining HIV Prevention: HIV Testing in Health Care Settings.
• The Wayne Fenton award and first awardee.
• The importance of Medical Department administration.
• Wayne Fenton and recovery.
• Wayne Fenton's impact on industry.
• Wayne Fenton: impact on food and drug administration.
• Wayne S. Fenton, MD: a patient's perspective.